Spectinomycin injection: dosage administration
Spectinomycin injection is indicated in the treatment of acute gonorrhea, urethritis and proctitis in the male, cervicitis and proctitis in the female when due to susceptible strains of N. gonorrhoeae.
Dosage and administration
Usually inject 5ml intramuscularly for a 2g dose. This is also the recommended dose for patients being treated after failure of previous antibiotic therapy. In geographic areas where antibiotic resistance is known to be prevalent, initial treatment with 4g (10ml) intramuscularly is preferred. The 10 ml injection may be divided between two gluteal injection sites. Intramuscular injections should be made deep into the upper outer quadrant of the gluteal muscle.
The use of spectinomycin HCL is contraindicated in patients found hypersensitive to it.
Spectinomycin hydrochloride is not effective in the treatment of syphilis . Antibiotic used in high doses for short periods of time to treat gonorrhea may mask or delay the symptoms of incubating syphilis. Since the treatment of syphilis demands prolonged therapy with an effective antibiotic, patients being treated for gonorrhea should be closely observed clinically. All patients with gonorrhea should have a serological test for syphilis at the time of diagnosis. Patients treated with spectinomycin hydrochloride should have a follow-up serological test for syphilis after three months.
The usual precautions should be observed with atopic individuals. The clinical effectiveness of spectinomycin hydrochloride should be monitored to detect evidence of development of resistance by N. gonorrhoea. Shake vials vigorously immediately after adding diluent and before withdrawing dose. It is recommended that disposable syringes and needles be used to avoid contamination with penicillin residue, especially when treating patients known to be highly sensitive to penicillin. Use of 20 gauge needle is recommended
Use in pregnancy
Safety for use in pregnancy has not been established.